Nutriband Advances Abuse-Deterrent Transdermal Drug Technology, Eyes $330 Million Market Potential
TL;DR
Nutriband (NASDAQ: NTRB) anticipates $200M & $130M peak sales for AVERSA Fentanyl & Buprenorphine, targeting pivotal clinical trials and NDA filings.
Nutriband is advancing AVERSA technology with Kindeva Drug Delivery, transitioning from feasibility to commercial development, raising $8.4M in non-brokered placement.
Nutriband aims to prevent drug abuse through AVERSA technology, expanding global patent portfolio to 46 countries, expecting revenue growth from partnerships in 2025.
Nutriband raises $8.4M, expands global patent portfolio, and collaborates with Kindeva Drug Delivery to advance AVERSA technology and prevent drug abuse.
Nutriband Inc. (NASDAQ: NTRB) is making substantial progress in developing abuse-deterrent transdermal pharmaceutical technologies, with significant milestones set for 2024 and 2025. The company is collaborating with Kindeva Drug Delivery to advance its AVERSA technology for fentanyl and buprenorphine patches, targeting a pivotal Human Abuse Liability clinical trial and New Drug Application (NDA) filing.
The company's strategic focus centers on its innovative AVERSA technology, designed to prevent drug abuse, misuse, diversion, and accidental exposure. Nutriband projects peak annual sales of up to $200 million for its AVERSA Fentanyl patch and $130 million for its AVERSA Buprenorphine patch, representing a potential $330 million market opportunity.
In addition to its pharmaceutical development, Nutriband has significantly expanded its global intellectual property portfolio, securing patents in 46 countries. The company also recently raised $8.4 million through a non-brokered placement, providing financial resources to support its commercialization efforts.
The company anticipates continued revenue growth in 2025 through its Pocono Pharma subsidiary, which has established a partnership with KT Tape. This diversification strategy demonstrates Nutriband's commitment to expanding its market presence and financial stability.
Nutriband's advances could have significant implications for addressing the opioid crisis by developing pharmaceutical technologies that reduce the potential for drug abuse and accidental exposure. The company's innovative approach positions it as a potential leader in creating safer pharmaceutical delivery systems.
Curated from InvestorBrandNetwork (IBN)